Vyome Holdings, Inc. HIND 深 滬
已收盤 05-15 16:00:00 美东时间
1.89
-0.030
-1.56%
華盛通- 最 高1.93
- 今 開1.93
- 成交量 2.19万股
- 最 低 1.85
- 昨 收 1.92
- 總市值 1326.50万
- 52周最高 16.00
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 1.75
- 委 比 20.00%
- 總股本 701.85万
- 歷史最高 22.40
- 量 比 0.27
- 振 幅 4.17%
- 歷史最低 0.018
- 每 手 1
- 風險率 2.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting
Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of
04-22 20:05
Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR
Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer ResearchVyome Holdings, Inc. ("Vyome")
04-06 20:06
美股夜盘 | Urgent.ly Inc.涨160.59%，STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%
Urgent.ly Inc.涨160.59%；STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%；Click Holdings Limited Class A涨53.06%
03-16 10:02
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a current VT-1953
02-11 20:07
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers ENvue Medical (NASDAQ:FEED) stock moved upwards by 19.0% to $1.25 duri...
01-28 20:05
Independent Analysis Estimates Vyome Holdings' VT-1953 At ~$1B Post-Phase 3 Value, And ~$600M Annual Peak Sales Potential
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billionModeled peak annual U.S. sales approaching USD 600 million for VT-1953Independent valuation analysis estimates
01-27 21:07
Vyome Holdings' Subsidiary LiveChain Enters Binding LOI To Acquire Humanyze Convertible Note In Equity Exchange with Remus Capital
Entry into a Material Definitive Agreement Letter of Intent with LICH and Remus: On December 17, 2025, Vyome Holdings, Inc. (the "Company") entered into a binding letter of intent (the "LOI") among, the
2025-12-24 05:17
Vyome's VT-1953 Announces Phase 2 Efficacy In Malignant Fungating Wounds, Paving Path To Pivotal Trial
VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002).Patient-reported impact of bad
2025-12-08 21:10
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MSP Recovery (NASDAQ:MSPR) stock increased by 36.4% to $0.3 during Fri...
2025-11-01 05:07
Vyome Holdings Acquires AI Startup Oculo, Inc.
Vyome Holdings ( ($HIND) ) has provided an announcement. On September 29, 2025,...
2025-10-04 04:57
